Correlation Between Molecular Partners and Nurix Therapeutics

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Nurix Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Nurix Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and Nurix Therapeutics, you can compare the effects of market volatilities on Molecular Partners and Nurix Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Nurix Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Nurix Therapeutics.

Diversification Opportunities for Molecular Partners and Nurix Therapeutics

0.46

Correlation Coefficient

Molecular Partners  Nurix Therapeutics

Very weak diversification

The 3 months correlation between Molecular and Nurix is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Nurix Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nurix Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Nurix Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nurix Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and Nurix Therapeutics go up and down completely randomly.

Pair Corralation between Molecular Partners and Nurix Therapeutics

Given the investment horizon of 90 days Molecular Partners AG is expected to generate 1.05 times more return on investment than Nurix Therapeutics. However, Molecular Partners is 1.05 times more volatile than Nurix Therapeutics. It trades about -0.08 of its potential returns per unit of risk. Nurix Therapeutics is currently generating about -0.14 per unit of risk. If you would invest  575.00  in Molecular Partners AG on October 6, 2024 and sell it today you would lose (88.00) from holding Molecular Partners AG or give up 15.3% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Molecular Partners AG  vs.  Nurix Therapeutics

Molecular Partners

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

Nurix Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Nurix Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong forward indicators, Nurix Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Molecular Partners and Nurix Therapeutics

The main advantage of trading using opposite Molecular Partners and Nurix Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Nurix Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nurix Therapeutics will offset losses from the drop in Nurix Therapeutics' long position.

The idea behind Molecular Partners AG and Nurix Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.